George Fromm

George Fromm

Company: Shattuck Labs

Job title: VP R&D

Seminars:

Panel Discussion: Combination vs. Single Agent Therapy: What Does the Future Look Like? 4:00 pm

• Discussing the advantages and challenges of single agent vs. combination of myeloid therapies with existing treatment regimens • Highlighting areas of need in combinations based on mechanistic understanding and medical need • Considering the challenges of multi-agent therapy with toxicity and demonstrating added benefit of combination therapy to regulatorsRead more

day: Day One

Sharing Preclinical Findings of Myeloid-Targeting Therapies in Combination with Immunotherapy to Demonstrate Added Therapeutic Benefit 5:00 pm

• Stating the goal of deploying myeloid-directed therapy in combination with immunotherapy and sharing mechanistic rationale • Presenting preclinical and translational findings of combination therapies • Separating the single agent effect of tumor myeloid therapies to demonstrate added benefit in combination • Discussing how to combine myeloid therapies with experimental therapies earlier in development, and…Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.